Hamburg

• EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Met … Ended
  2024-515407-19-00 5 2023-08-16 Metastatic pancreatic ductal adenocarcinoma (mPDAC)
• A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.78 … Ended
  2022-502045-10-00 4 2023-08-11 Atopic dermatitis
• The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the tr … Ended
  2022-500449-26-00 6 2023-08-03 Type 2 diabetes mellitus (T2DM)
• Clinical trial of MK-7648A in adults and children with skin cancer Ended
  2022-501417-31-01 5 2023-08-01 melanoma
• A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV … Ended
  2022-502620-49-00 2 2023-08-01 Resected Melanoma Stage III or Stage IV
• UNITAS Ended
  2022-502483-21-00 4 2023-07-28 Insomnia disorder
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended
  2022-502234-70-00 5 2023-07-14 Chronic Obstructive Pulmonary Disease (COPD)
• A multicentre, single arm trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 1 … Ended
  2022-502023-21-00 5 2023-07-12 Prevention of pregnancy
• A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgest … Ended
  2022-502024-51-00 5 2023-07-12 Prevention of pregnancy
• A STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WIT … Ended
  2022-501794-39-00 5 2023-06-28 Uveitic Macular Edema
• Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (Neo … Ended
  2024-515660-31-00 4 2023-06-27 intrahepatic cholangiocarcinoma
• Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Ended
  2024-512554-15-00 5 2023-06-21 COVID-19
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501752-29-00 5 2023-06-15 Hidradenitis Suppurativa
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 5 2023-06-08 Moderately to severely active ulcerative colitis
• A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended
  2022-500101-41-00 6 2023-06-07 Type 2 Diabetes
• This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended
  2023-504869-23-00 11 2023-05-31 Dermatitis atopic
• A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera … Ended
  2022-502575-30-00 5 2023-05-23 Atopic Dermatitis
• Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended
  2022-501585-22-00 5 2023-05-11 Atopic Dermatitis
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th … Ended
  2022-500121-33-01 5 2023-05-08 Anti-GBM antibody disease (Goodpasture disease)
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25 Atopic Dermatitis
• Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Ped … Ended
  2023-507144-36-00 5 2023-04-20 Juvenile psoriatic arthritis
• A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is Ended
  2022-501362-22-00 10 2023-04-18 Psoriatic Arthritis
• An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended
  2022-501850-12-00 4 2023-03-15 Psoriasis
• Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Witho … Ended
  2023-510470-13-00 4 2023-03-10 Overweight and Obesity

Showing 937–960 of 1,087 trials